23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
14:45 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

FDA issues CRL to NDA for Vernalis' CCP-08

Vernalis plc (LSE:VER) said FDA issued a complete response letter to an NDA for CCP-08 to treat cough and cold. The letter follows a CRL issued in April for its other cough and cold candidate...
23:35 , Aug 7, 2017 |  BC Extra  |  Company News

Vernalis gets another CRL in cough and cold pipeline

Vernalis plc (LSE:VER) lost 2p (11%) to 17p Monday after it said FDA issued a complete response letter to an NDA for CCP-08 to treat cough and cold. The letter follows a CRL issued...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
22:00 , Dec 30, 2016 |  BC Week In Review  |  Clinical News

CCP-08 regulatory update

Vernalis and Tris said FDA accepted for review an NDA for CCP-08, an undisclosed, extended-release cough and cold product. The PDUFA date is Aug. 4. The NDA acceptance triggered an undisclosed milestone payment to Tris...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Tris Pharma, Vernalis Group deal

The partners said Tris achieved a milestone under a February 2012 deal granting Vernalis exclusive, North American rights to commercialize up to six reformulated prescription cough and cold products using Tris’ OralXR+ extended-release formulation technology....